Former Zantac Users That Switch To The New Zantac 360 Could Suffer Harsher Side Effects

Zantac 360 is not an everyday go-to heartburn medicine like the original Zantac and could lead to a variety of medical problems

Wednesday, September 8, 2021 - Doctors are concerned that former Zantac users are switching to the new Zantac 360 over concerns about developing heartburn medicine cancer, without regard to the toxic side effects the latter carries. People who cannot obtain Zantac, the preferred brand of ranitidine heartburn pain relief due to the recall, have turned to a similar type of medicine called famotidine, the active ingredient in Zantac 360. Sanofi, the maker of Zantac, has recalled all of their stock of ranitidine and now markets Zantac 360 famotidine as a replacement. Zantac 360 famotidine is a far stronger and longer-lasting form of heartburn pain relief. Zantac was originally an H2 receptor blocker drug but has been repackaged as a protein pump inhibitor (PPI). Pepcid was the leading brand of PPI famotidine when Zantac was recalled by the FDA on April 1, 2020, over concerns it contained levels of NDMA, a carcinogen, above the acceptable limit. Heartburn medicine is one of the most overused drugs because most heartburn symptoms could be eliminated with minimal dietary and lifestyle changes. All a person must do to alleviate heartburn pain relief is to stop smoking or drinking, and avoid eating spicy, oily foods that are rich in animal fat, in most instances. People that take heartburn medicine are usually overweight. A person who wishes to alleviate heartburn and other discomforts after eating should gradually lose weight by eating less and exercising more. Heartburn sufferers should be advised that Zantac 360 is about 7.5 times stronger than regular Zantac ranitidine, and carries serious side effects. GastroHeatlh says "a 20 mg famotidine is equivalent to 150 mg ranitidine." According to DrugGenius.com, famotidine's side effects include: "constipation and diarrhea, fatigue, dizziness and weakness, mood swings, headaches, insomnia, muscle pain and joint pain dry mouth, and nausea or vomiting." Sanofi is misleading the public when they say that the new Zantac 360 is merely "Extra Strength," a designation that seems harmless enough on the surface.

Studies show that people in Scotland and elsewhere that took ranitidine had a 22 percent greater chance of developing bladder cancer. People in the United States that have developed stomach, bladder, esophageal, prostate, and colon cancer have filed Zantac cancer lawsuits. Hundreds of Zantac cancer lawsuits will be adjudicated one by one after having been consolidated into multidistrict litigation (MDL) to avoid repeating administrative court procedures hundreds of times. Science hearings in the coming months will focus on deciding if ranitidine is an inherently unstable molecule that naturally degrades into NDMA, or if the spike in NDMA is due to overheating it during the testing process. Deciding this issue could be the difference between Zantac litigation being one of the largest mass-tort personal injury actions, or just an exaggeration generated by an online startup company looking to make a name for themselves. For the record, the FDA sides with the later categorization and when they tested ranitidine found little if any increases in NDMA above the 96 nanograms per pill per day limit the agency previously placed.

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.